<DOC>
	<DOCNO>NCT01728519</DOCNO>
	<brief_summary>Birch pollen allergic patient currently treat subcutaneous injection pollen extract either standard allergen specific immunotherapy ( SIT ) ultra-rush immunotherapy . Such treatment prone side effect perform hospital environment due risk potential anaphylactic reaction . The aim study test new product AllerT expect show widely reduce side effect . AllerT inject via two different route , subcutaneous versus intradermal . The primary endpoint study local systemic safety repeat injection product . Since AllerT provide patient pre-seasonal treatment decrease seasonal allergic symptom , also evaluate potential efficacy approach use nasal provocation test ( NPT ) birch pollen</brief_summary>
	<brief_title>Phase I/IIa Clinical Evaluation AllerT v Placebo Subjects Allergic Birch Pollen</brief_title>
	<detailed_description>In addition initial protocol , post hoc evaluation conduct , new ethic committee review , ass quality life birch pollen season follow trial ( April 2009 ) obtain blood sample evaluation immunology marker IgG4 IgE season 2010 ( July 2010 ) season 2012 ( July 2012 ) ,</detailed_description>
	<mesh_term>Rhinitis , Allergic</mesh_term>
	<mesh_term>Rhinitis</mesh_term>
	<criteria>Allergic rhinitis symptom pollen season preceding study , confirm SPT ( prick test ) and/or positive specific IgE CAP test birch pollen ( class I minimum ) Positive SPT Bet v 1 ( prick test ) , negative SPT AllerT receive immunotherapy allergen within 3 year start study . symptomatic perennial allergen active seasonal allergy trial . non control asthma ( peak flow lower 30 % predict value ) . history severe medical condition able influence course study Any confirm suspected immunodeficiency condition , include human immunodeficiency virus ( HIV ) infection asplenia . Subjects immunosuppressive medication . Pregnant lactate woman woman willing intend become pregnant study . Any significant finding , opinion investigator , would increase risk adverse outcome participate protocol drop study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>November 2012</verification_date>
	<keyword>Allergy</keyword>
	<keyword>Birch Pollen</keyword>
	<keyword>Immunotherapy</keyword>
</DOC>